197 related articles for article (PubMed ID: 34492368)
1. Comparative evaluation of agar dilution and broth microdilution by commercial and in-house plates for Bacteroides fragilis group: An economical and expeditious approach for resource-limited settings.
Sood A; Angrup A; Ray P; Bala K
Anaerobe; 2021 Oct; 71():102443. PubMed ID: 34492368
[TBL] [Abstract][Full Text] [Related]
2. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates.
Nagy E; Justesen US; Eitel Z; Urbán E;
Anaerobe; 2015 Feb; 31():65-71. PubMed ID: 25464140
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of microdilution trays (sensititre) for antimicrobial susceptibility testing of Bacteroides fragilis.
Dornbusch K; Lindmark A; Nord CE
Med Microbiol Immunol; 1978 Oct; 165(3):147-51. PubMed ID: 723780
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic resistance pattern of Bacteroides fragilis isolated from clinical and colorectal specimens.
Jasemi S; Emaneini M; Ahmadinejad Z; Fazeli MS; Sechi LA; Sadeghpour Heravi F; Feizabadi MM
Ann Clin Microbiol Antimicrob; 2021 Apr; 20(1):27. PubMed ID: 33892721
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility results for the Bacteroides fragilis group: comparison of the broth microdilution and agar dilution methods.
Hecht DW; Lederer L; Osmolski JR
Clin Infect Dis; 1995 Jun; 20 Suppl 2():S342-5. PubMed ID: 7548593
[TBL] [Abstract][Full Text] [Related]
7. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
8. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.
Karlowsky JA; Walkty AJ; Adam HJ; Baxter MR; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2012 Mar; 56(3):1247-52. PubMed ID: 22203594
[TBL] [Abstract][Full Text] [Related]
10. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
Yim J; Lee Y; Kim M; Seo YH; Kim WH; Yong D; Jeong SH; Lee K; Chong Y
Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287
[TBL] [Abstract][Full Text] [Related]
12. Geographic patterns of antimicrobial susceptibilities for Bacteroides spp. worldwide: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2007-2020.
Wu PH; Chen CH; Lin HH; Tseng KH; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jul; 62(1):106822. PubMed ID: 37088437
[TBL] [Abstract][Full Text] [Related]
13. Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
J Clin Microbiol; 1987 Apr; 25(4):645-9. PubMed ID: 3571474
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.
Aldridge KE; Wexler HM; Sanders CV; Finegold SM
Antimicrob Agents Chemother; 1990 Jan; 34(1):179-81. PubMed ID: 2327757
[TBL] [Abstract][Full Text] [Related]
15. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
Aldridge KE; Ashcraft D; O'Brien M; Sanders CV
Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the E-test for susceptibility testing of the Bacteroides fragilis group. Danish study group.
Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
APMIS; 1994 Jun; 102(6):446-50. PubMed ID: 8068304
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of VITEK MS, Clin-ToF-II MS, Autof MS 1000 and VITEK 2 ANC card for identification of Bacteroides fragilis group isolates and antimicrobial susceptibilities of these isolates in a Chinese university hospital.
Wang Y; Chen XF; Xie XL; Xiao M; Yang Y; Zhang G; Zhang JJ; Duan SM; Zhang Q; Zhang P; Tsui C; Xu YC
J Microbiol Immunol Infect; 2019 Jun; 52(3):456-464. PubMed ID: 30772212
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the E test (PDM epsilometer) and broth microdilution susceptibility tests for members of the Bacteroides fragilis group.
Murray PR; Niles AC
Diagn Microbiol Infect Dis; 1991; 14(6):501-5. PubMed ID: 1802537
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Schaumann R; Funke M; Janssen E; Rodloff AC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
[TBL] [Abstract][Full Text] [Related]
20. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.
García-Rodríguez JE; García-Sánchez JE
Rev Infect Dis; 1990; 12 Suppl 2():S142-51. PubMed ID: 2305180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
